NasdaqCM - Delayed Quote USD
TG Therapeutics, Inc. (TGTX)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 7:59 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 0.02 | 0.08 | 0.15 | 0.75 |
| Low Estimate | -0.05 | 0.02 | -0.04 | 0.33 |
| High Estimate | 0.05 | 0.14 | 0.58 | 1.06 |
| Year Ago EPS | 0.73 | -0.1 | 0.09 | 0.15 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 81.23M | 98.42M | 328.37M | 495.15M |
| Low Estimate | 76.7M | 92.8M | 307.26M | 373.79M |
| High Estimate | 85.44M | 105M | 411.69M | 574.9M |
| Year Ago Sales | 46.56M | 43.97M | 233.66M | 328.37M |
| Sales Growth (year/est) | 74.50% | 123.80% | 40.50% | 50.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.12 | -0.1 | -0.04 | -0.05 |
| EPS Actual | 0.73 | -0.1 | -0.07 | 0.04 |
| Difference | 0.61 | 0 | -0.03 | 0.09 |
| Surprise % | 508.30% | 0.00% | -75.00% | 180.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.02 | 0.08 | 0.15 | 0.75 |
| 7 Days Ago | 0.02 | 0.08 | 0.15 | 0.75 |
| 30 Days Ago | 0.02 | 0.08 | 0.15 | 0.75 |
| 60 Days Ago | 0.02 | 0.08 | 0.15 | 0.76 |
| 90 Days Ago | -0.01 | 0.04 | -0.01 | 0.59 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TGTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -97.30% | -- | -- | 3.60% |
| Next Qtr. | 180.00% | -- | -- | 7.90% |
| Current Year | 66.70% | -- | -- | 2.50% |
| Next Year | 400.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/18/2024 |
| Maintains | B. Riley Securities: Buy to Buy | 8/7/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 8/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/6/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/2/2024 |
| Maintains | Ladenburg Thalmann: Buy to Buy | 5/2/2024 |
Related Tickers
IOVA Iovance Biotherapeutics, Inc.
9.92
-3.12%
AXSM Axsome Therapeutics, Inc.
91.50
-1.98%
VKTX Viking Therapeutics, Inc.
64.34
-2.22%
URGN UroGen Pharma Ltd.
12.52
-1.65%
SMMT Summit Therapeutics Inc.
20.50
-3.35%
EXEL Exelixis, Inc.
28.66
-0.83%
ADMA ADMA Biologics, Inc.
15.62
-1.01%
LBPH Longboard Pharmaceuticals, Inc.
59.34
+0.22%
CKPT Checkpoint Therapeutics, Inc.
3.1800
+5.65%
FOLD Amicus Therapeutics, Inc.
12.01
+0.92%